Shares of CVS Health Corp (NYSE:CVS) ended Wednesday session in green amid volatile trading. The shares closed up +0.25 points or 0.27% at $93.61 with 3.35 million shares getting traded. Post opening the session at $93.18, the shares hit an intraday low of $92.86 and an intraday high of $93.81 and the price vacillated in this range throughout the day. The company has a market cap of $99.30 billion and the numbers of outstanding shares have been calculated to be 1.07 billion shares.
On Sept. 7, 2016 In its continuing commitment to help improve access to health care for all Americans, CVS Health (CVS) announced the rollout of Project Health, its annual free health services campaign, at select CVS Pharmacy locations in 10 multicultural communities across the country. Beginning Thursday, September 8 and running through December 18, nearly $8 million worth of free health services will be delivered at more than 500 Project Health events.
Since 2006, Project Health has delivered more than $112 million worth of free health care services to nearly 872,000 people, many of whom are uninsured or underinsured, demonstrating the continuing need for these critical services.
“Despite the increased number of Americans who have become insured over the past five years, there are still barriers to quality care, such as cost and access, for many patients,” said Troyen A. Brennan, M.D., M.P.H., Chief Medical Officer of CVS Health. “Project Health is part of CVS Health’s commitment to improving access to quality care by identifying health concerns and risk factors for participants who may not have otherwise sought preventative care.”
Project Health offers an array of free comprehensive health risk assessments, including blood pressure, Body Mass Index (BMI), glucose and total cholesterol screenings. Once screened, CVS Pharmacy helps patients through on-site consultations with bilingual (English/Spanish) nurse practitioners or physician assistants who will analyze results and refer patients who require additional medical attention to no-cost or low-cost medical facilities nearby or to their primary care physician. CVS pharmacists are also available to conduct one-on-one medication reviews and answer any questions patients may have.
“The Centers for Medicare & Medicaid Services (CMS) applauds CVS Health on their Project Health initiative,” said Kevin Counihan, Director and Marketplace Chief Executive Officer at the Centers for Medicare & Medicaid Services. “We thank them for their continued commitment to providing free health screenings and educational materials ensuring better health for many Americans.”
Shares of Medivation Inc (NASDAQ:MDVN) ended Wednesday session in green amid volatile trading. The shares closed up +0.13 points or 0.16% at $80.97 with 2.41 million shares getting traded. Post opening the session at $80.84, the shares hit an intraday low of $80.75 and an intraday high of $80.97 and the price vacillated in this range throughout the day. The company has a market cap of $13.43 billion and the numbers of outstanding shares have been calculated to be 165.93 million shares.
On August 22, 2016 Pfizer Inc. (PFE) and Medivation, Inc. (MDVN) announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer’s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in the first full year after close with additional accretion and growth anticipated thereafter. Pfizer does not expect the transaction to impact its current 2016 financial guidance.
“The proposed acquisition of Medivation is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Pfizer,” said Ian Read, Chairman and Chief Executive Officer, Pfizer. “The addition of Medivation will strengthen Pfizer’s Innovative Health business and accelerate its pathway to a leadership position in oncology, one of our key focus areas, which we believe will drive greater growth and scale of that business over the long-term. This transaction is another example of how we are effectively deploying our capital to generate attractive returns and create shareholder value.”